MCID: BLL006
MIFTS: 59

Bullous Pemphigoid

Categories: Rare diseases, Skin diseases, Immune diseases

Aliases & Classifications for Bullous Pemphigoid

MalaCards integrated aliases for Bullous Pemphigoid:

Name: Bullous Pemphigoid 12 50 56 14 69
Senile Dermatitis Herpetiformis 50 69
Benign Pemphigus 50 69
Pemphigoid, Bullous 42
Pemphigoid Bullous 52
Old Age Pemphigus 50
Parapemphigus 50
Pemphigoid 50

Characteristics:

Orphanet epidemiological data:

56
bullous pemphigoid
Age of onset: All ages;

Classifications:

Orphanet: 56  
Rare skin diseases


Summaries for Bullous Pemphigoid

NIH Rare Diseases : 50 bullous pemphigoid is a skin disorder characterized by large blisters. the blisters are usually located on the arms, legs, or middle of the body. in some people, the mouth or genitals are also affected. the blisters may break open and form ulcers or open sores. bullous pemphigoid usually occurs in older persons and is rare in young people. symptoms may come and go. in most patients, the condition goes away after several years. bullous pemphigoid is an autoimmune disorder which occurs when the body's immune system attacks and destroys healthy body tissue by mistake. treatment may include corticosteroids taken by mouth or applied to the skin. medicines that suppress the immune system may also be prescribed. for some, antibiotics in the tetracycline family are useful. last updated: 8/10/2016

MalaCards based summary : Bullous Pemphigoid, also known as senile dermatitis herpetiformis, is related to lymphoma and epidermolysis bullosa, and has symptoms including diabetes mellitus, eczema and urticaria. An important gene associated with Bullous Pemphigoid is COL17A1 (Collagen Type XVII Alpha 1 Chain), and among its related pathways/superpathways are ERK Signaling and Integrin Pathway. The drugs Omalizumab and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and testes, and related phenotypes are digestive/alimentary and immune system

Disease Ontology : 12 An autoimmune disease of skin and connective tissue characterized by large blisters.

Wikipedia : 72 Bullous pemphigoid is an acute or chronic autoimmune skin disease, involving the formation of blisters,... more...

Related Diseases for Bullous Pemphigoid

Diseases related to Bullous Pemphigoid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 260)
id Related Disease Score Top Affiliating Genes
1 lymphoma 30.5 CD79A COL17A1 DST IL5
2 epidermolysis bullosa 30.3 CCL11 CCL17 DSG1 IL5 RNASE3
3 subcorneal pustular dermatosis 30.3 CCL11 CD79A HLA-DQB1
4 lymphocytic colitis 30.0 CD79A HLA-DQB1 HLA-DRB1
5 dermatitis herpetiformis 28.3 CD79A COL17A1 DSG1 DSG3 DSP DST
6 lichen planus pemphigoides 11.3
7 autoimmune disease, multisystem, infantile-onset, 2 11.0
8 ligneous conjunctivitis 10.8 COL17A1 DST ITGB4
9 papillary follicular thyroid adenocarcinoma 10.8 IL5 RNASE3
10 x-linked intellectual disability-hypogammaglobulinemia-progressive neurological deterioration syndrome 10.7 DSG3 DSP
11 rectum carcinoma in situ 10.7 COL17A1 DST
12 lymphocytic gastritis 10.7 CCL11 IL5 RNASE3
13 fruit allergy 10.7 HLA-DQB1 HLA-DRB1
14 cannabis abuse 10.7 CCL11 IL5 RNASE3
15 trachea leiomyoma 10.7 CCL11 IL5 RNASE3
16 female urethral cancer 10.7 CCL11 IL5 RNASE3
17 viljoen kallis voges syndrome 10.7 CCL11 IL5 RNASE3
18 breast hemangiopericytoma 10.7 HLA-DQB1 HLA-DRB1
19 purpura fulminans 10.7 HLA-DQB1 IL5 RNASE3
20 arrhythmogenic right ventricular dysplasia 10 10.7 DSG1 DSP
21 biemond syndrome 10.6 HLA-DQB1 HLA-DRB1
22 inflamed seborrheic keratosis 10.6 CCL11 IL5 RNASE3
23 light chain deposition disease 10.6 COL17A1 HLA-DQB1 HLA-DRB1
24 eyelid neoplasm 10.6 CCL11 IL5 RNASE3
25 acute contagious conjunctivitis 10.6 CCL11 IL5 RNASE3
26 dentin caries 10.6 CCL11 IL5 RNASE3
27 benign mammary dysplasia 10.6 CCL11 IL5 RNASE3
28 juvenile sialidosis type 2 10.6 HLA-DQB1 HLA-DRB1
29 corneal intraepithelial neoplasm 10.6 CCL11 IL5 RNASE3
30 muscular dystrophy, limb-girdle, type 2q 10.6 ITGB4 PLEC
31 colon adenocarcinoma 10.6 CCL11 IL5 RNASE3
32 heart septal defect 10.6 CD79A RNASE3
33 spontaneous ocular nystagmus 10.6 CCL11 IL5 RNASE3
34 ragweed sensitivity 10.6 CCL11 IL5 RNASE3
35 idiopathic subglottic tracheal stenosis 10.6 HLA-DQB1 HLA-DRB1
36 antley-bixler syndrome with genital anomalies and disordered steroidogenesis 10.6 CCL11 DSG1 IL5
37 anterior dislocation of lens 10.6 CCL11 RNASE3
38 inner ear disease 10.6 CCL11 IL5 RNASE3
39 ischio-vertebral syndrome 10.5 DSG1 PPL
40 reese retinal dysplasia 10.5 HLA-DQB1 HLA-DRB1
41 central sleep apnea 10.5 COL17A1 DSG3 DST
42 mosaic trisomy 1 10.5 HLA-DQB1 HLA-DRB1
43 intellectual disability-short stature-hypertelorism syndrome 10.5 DSG1 DSG3 DST
44 cholesteatoma of middle ear 10.5 CCL11 CD79A IL5
45 crustacean allergy 10.5 CD79A IL5 RNASE3
46 fbxl4-related encephalomyopathic mitochondrial dna depletion syndrome 10.5 ITGA6 ITGB4 PLEC
47 conjunctival concretion 10.5 CCL11 DSG1 IL5
48 epidermolysis bullosa simplex, ogna type 10.5 COL17A1 DST PLEC
49 isolated scaphocephaly 10.5 DSG1 DSG3
50 pemphigus 10.5

Comorbidity relations with Bullous Pemphigoid via Phenotypic Disease Network (PDN):


Acute Cystitis Decubitus Ulcer
Deficiency Anemia Heart Disease
Pemphigus Protein-Energy Malnutrition
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Bullous Pemphigoid:



Diseases related to Bullous Pemphigoid

Symptoms & Phenotypes for Bullous Pemphigoid

Human phenotypes related to Bullous Pemphigoid:

56 32 (show all 11)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 diabetes mellitus 56 32 hallmark (90%) Very frequent (99-80%) HP:0000819
2 eczema 56 32 hallmark (90%) Very frequent (99-80%) HP:0000964
3 urticaria 56 32 hallmark (90%) Very frequent (99-80%) HP:0001025
4 weight loss 56 32 hallmark (90%) Very frequent (99-80%) HP:0001824
5 recurrent infections 56 32 hallmark (90%) Very frequent (99-80%) HP:0002719
6 autoimmunity 56 32 hallmark (90%) Very frequent (99-80%) HP:0002960
7 abnormal blistering of the skin 56 32 hallmark (90%) Very frequent (99-80%) HP:0008066
8 erythema 56 32 hallmark (90%) Very frequent (99-80%) HP:0010783
9 macule 56 32 hallmark (90%) Very frequent (99-80%) HP:0012733
10 psoriasis 56 Frequent (79-30%)
11 psoriasiform dermatitis 32 frequent (33%) HP:0003765

MGI Mouse Phenotypes related to Bullous Pemphigoid:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.91 DSG3 DSP HLA-DQB1 IL5 ITGA6 ITGB4
2 immune system MP:0005387 9.9 CCL11 CCL17 CD79A DSG3 HLA-DQB1 IL5
3 craniofacial MP:0005382 9.87 DSG3 DSP ITGA6 ITGB4 LAMA3 LAMB3
4 integument MP:0010771 9.61 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2 PLEC
5 respiratory system MP:0005388 9.28 CCL11 DSG3 HLA-DQB1 IL5 ITGA6 ITGB4

Drugs & Therapeutics for Bullous Pemphigoid

Drugs for Bullous Pemphigoid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Omalizumab Approved, Investigational Phase 4 242138-07-4
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3
Clobetasol Investigational Phase 4,Phase 3,Phase 2 25122-46-7, 25122-41-2 32798 5311051
4 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
5 glucocorticoids Phase 4,Phase 3,Phase 2
6 Hormone Antagonists Phase 4,Phase 3,Phase 2
7 Hormones Phase 4,Phase 3,Phase 2
8 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
9 Anti-Allergic Agents Phase 4
10 Anti-Asthmatic Agents Phase 4
11 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
12 Antineoplastic Agents, Hormonal Phase 4
13 Immunoglobulin E Phase 4
14 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
15 Respiratory System Agents Phase 4
16
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
17
rituximab Approved Phase 3,Phase 1,Phase 2 174722-31-7 10201696
18
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2 128794-94-5 5281078
19
Mycophenolic acid Approved Phase 3,Phase 2 24280-93-1 446541
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
21
leucovorin Approved, Nutraceutical Phase 3 58-05-9 143 6006
22 Antimetabolites Phase 3,Phase 2,Phase 1
23 Antimetabolites, Antineoplastic Phase 3,Phase 2
24 Antirheumatic Agents Phase 3,Phase 2,Phase 1
25 Dermatologic Agents Phase 3,Phase 1,Phase 2
26 Folic Acid Antagonists Phase 3
27 Immunosuppressive Agents Phase 3,Phase 2
28 Nucleic Acid Synthesis Inhibitors Phase 3
29 Vitamin B Complex Phase 3,Phase 1,Phase 2
30 gamma-Globulins Phase 3,Phase 2,Phase 1
31 Immunoglobulins, Intravenous Phase 3,Phase 2,Phase 1
32 Rho(D) Immune Globulin Phase 3,Phase 2,Phase 1
33 Anti-Bacterial Agents Phase 3,Phase 2
34 Antibiotics, Antitubercular Phase 3,Phase 2
35 Alkylating Agents Phase 3
36 Folate Nutraceutical Phase 3,Phase 1,Phase 2
37 Vitamin B9 Nutraceutical Phase 3,Phase 1,Phase 2
38
Leflunomide Approved, Investigational Phase 2 75706-12-6 3899
39
Azathioprine Approved Phase 2 446-86-6 2265
40
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
41
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
42
Infliximab Approved Phase 1, Phase 2 170277-31-3
43
Riboflavin Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 83-88-5 493570
44 Gastrointestinal Agents Phase 1, Phase 2
45 Methylprednisolone acetate Phase 2
46 Methylprednisolone Hemisuccinate Phase 2
47 Prednisolone acetate Phase 2
48 Prednisolone hemisuccinate Phase 2
49 Prednisolone phosphate Phase 2
50 Micronutrients Phase 1, Phase 2

Interventional clinical trials:

(show all 45)

id Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Omalizumab in Bullous Pemphigoid Completed NCT00472030 Phase 4 Omalizumab;prednisone
2 Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous Pemphigus Completed NCT00213421 Phase 4 Dermoval
3 Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid Recruiting NCT02360202 Phase 4 Clobetasol Propionate cream treatment
4 Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid Unknown status NCT02313870 Phase 3 clobetasol propionate + Methotrexate;clobetasol propionate alone
5 Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid Completed NCT00525616 Phase 3 Mabthera
6 Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids Completed NCT01408550 Phase 3 NPB-01;Placebo
7 Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid. Recruiting NCT02993133 Phase 3 Cellcept® in autoimmune bullous dermatoses
8 Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid Not yet recruiting NCT03295383 Phase 3 Rituximab 1g IV;Cyclophosphamide 50Mg Oral Tablet;Placebo of Rituximab;Placebo Oral Tablet
9 Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid Unknown status NCT00802243 Phase 2 leflunomide
10 Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids. Completed NCT00809822 Phase 2 NPB-01;Placebo
11 Rituximab in the Treatment of Patients With Bullous Pemphigoid Completed NCT00286325 Phase 1, Phase 2 Rituximab
12 Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid Completed NCT00431119 Phase 2 Azathioprine or Mycophenolate mofetil
13 Anti-IL-5 Therapy in Bullous Pemphigoid (BP) Completed NCT01705795 Phase 2 Mepolizumab (a-IL-5 antibody);Placebo
14 Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid Completed NCT00584935 Phase 1, Phase 2 Rituximab
15 Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
16 Ixekizumab in the Treatment of Bullous Pemphigoid Recruiting NCT03099538 Phase 2 Ixekizumab
17 A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid Recruiting NCT03286582 Phase 2 AC-203 1% Topical Ointment;Clobetasol 0.05% Topical Ointment
18 Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid Recruiting NCT02226146 Phase 2
19 Limbal Epithelial Stem Cell Transplantation: a Phase II Multicenter Trial Recruiting NCT02318485 Phase 2
20 Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment Terminated NCT01688882 Phase 2 QGE031;Placebo
21 Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid Terminated NCT01571895 Phase 2 DF2156A
22 Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Withdrawn NCT02126020 Phase 1, Phase 2 topical infliximab
23 The Improvement of Limbal Epithelial Culture Technique by Using Collagenase to Isolate Limbal Stem Cells Unknown status NCT02202642 Phase 1
24 Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies Completed NCT00691210 Phase 1 Vorinostat;Niacinamide;Etoposide
25 Safety, Tolerability and Activity of TNT009 in Healthy Volunteers and Patients With Complement Mediated Disorders Recruiting NCT02502903 Phase 1 TNT009
26 Topical Infliximab for Sterile Corneal Melt Recruiting NCT02987686 Phase 1 Topical Infliximab
27 Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions Withdrawn NCT02042027 Phase 1 Gamunex-C
28 Explore the Mechanisms of Pruritus in Bullous Pemphigoid Patients During Remission Unknown status NCT01265082
29 Wound Dressings for Pemphigus and Pemphigoid Unknown status NCT02365675
30 Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid Completed NCT02883894
31 Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients Completed NCT03320798
32 Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study Completed NCT00116090
33 A Study of the Association of Sleep Dysfunction and Burning Mouth Syndrome Completed NCT00862576
34 Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid Recruiting NCT02837965 treatment with topical superpotent corticosteroid therapy;treatment with systemic therapy (methotrexate);treatment systemic therapy (prednisone);treatment with systemic therapy (prednisone);treatment with systemic therapy (doxycycline)
35 Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid Recruiting NCT02874079
36 Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid Recruiting NCT01559155
37 Pruritus and Pemphigoid in Nursing Home Patients Recruiting NCT02823067
38 Autoimmune Blistering Diseases Study Recruiting NCT02753777
39 Identification of Vulnerability Factors in the Course of Pemphigus Patients Recruiting NCT02237313
40 Register of Autoimmune Bullous Dermatoses Recruiting NCT02899923
41 Prevalence of Cutaneous Autoimmune Phenomena in HIV Infected Patients Recruiting NCT03129308
42 Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation Available NCT02149732
43 Immune Responses to Antigens in Non-infectious Eye Inflammatory Diseases Enrolling by invitation NCT00357071
44 Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid Not yet recruiting NCT03272958
45 Serum FFA Desaturase Activity Index in Patients on High Dose Corticosteroids Not yet recruiting NCT02872584 Prednisone

Search NIH Clinical Center for Bullous Pemphigoid

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: pemphigoid, bullous

Genetic Tests for Bullous Pemphigoid

Anatomical Context for Bullous Pemphigoid

MalaCards organs/tissues related to Bullous Pemphigoid:

39
Skin, Eye, Testes, T Cells, Neutrophil, B Cells, Breast

Publications for Bullous Pemphigoid

Articles related to Bullous Pemphigoid:

(show top 50) (show all 977)
id Title Authors Year
1
Bullous pemphigoid with IgG autoantibodies to the I+3 subunit of laminin 332 associated with psoriasis vulgaris. ( 28468743 )
2017
2
A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200a88mg/day) with that of oral prednisolone (0.5a88mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial. ( 28406394 )
2017
3
Doxycycline compared to prednisolone therapy for patients with bullous pemphigoid: cost-effectiveness analysis of the BLISTER trial. ( 28940316 )
2017
4
Membranous glomerulonephropathy in a patient with bullous pemphigoid. ( 28509127 )
2017
5
Positive clinical outcome in a patient with recalcitrant bullous pemphigoid treated with rituximab and intravenous immunoglobulin. ( 28508388 )
2017
6
The Leukotriene B4 and its Receptor BLT1A ActA as Critical Drivers of Neutrophil Recruitment in Murine Bullous Pemphigoid-Like Epidermolysis Bullosa Acquisita. ( 28108297 )
2017
7
Serum levels and tissue expression of interleukin-31 in dermatitis herpetiformis and bullous pemphigoid. ( 28465041 )
2017
8
IgE auto-reactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants. ( 28868796 )
2017
9
Incidence of bullous pemphigoid in Sweden 2005-2012: a nationwide population-based cohort study of 3761 patients. ( 28875235 )
2017
10
Image Gallery: Juvenile cutaneous chronic graft-versus-host disease presenting as bullous pemphigoid. ( 28940263 )
2017
11
Three new cases of bullous pemphigoid during anti-PD-1 antibody therapy. ( 28865162 )
2017
12
Immunoglobulin E Autoantibodies in Bullous Pemphigoid Detected by Immunoglobulin E Enzyme-Linked Immunosorbent Assays. ( 27829077 )
2017
13
Langerhans cells are predominant high affinity immunoglobulin E receptor bearing cells in the epidermis of bullous pemphigoid skin. ( 27839901 )
2017
14
Multimorbidity in Bullous Pemphigoid: a case-control analysis of BP patients with age and gender matched controls. ( 28485892 )
2017
15
An open, multicenter, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. ( 28494097 )
2017
16
Bullous Pemphigoid associated with Dipeptidyl Peptidase-4 Inhibitors: A Report of Five Cases. ( 28520234 )
2017
17
Bullous Pemphigoid Successfully Treated With a Combination Therapy of Plasmapheresis Followed by Intravenous High Dose Immunoglobulin. ( 28378368 )
2017
18
Successful Management of Acquired Hemophilia A Associated with Bullous Pemphigoid: A Case Report and Review of the Literature. ( 28458935 )
2017
19
A Case of Wolf's Isotopic Response Presenting as Bullous Pemphigoid. ( 28761305 )
2017
20
Photodynamic Therapy Effective for the Treatment of Actinic Keratosis and Basal Cell Carcinoma in Bullous Pemphigoid Patients. ( 28373119 )
2017
21
Distinguishing Epidermolysis Bullosa Acquisita From Bullous Pemphigoid Without Direct Immunofluorescence. ( 28719980 )
2017
22
Elevated IL-31 serum levels in bullous pemphigoid patients correlate with eosinophil numbers and are associated with BP180-IgE. ( 28823642 )
2017
23
Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid. ( 28355425 )
2017
24
Survey of bullous pemphigoid in an Italian University hospital: clinical-epidemiological characteristics and follow-up. ( 28079339 )
2017
25
Reply to: Direct Immunofluorescence Findings in Discoid Lupus Erythematosus and Bullous Pemphigoid. ( 28323786 )
2017
26
Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity. ( 27829102 )
2017
27
Case of bullous pemphigoid accompanied by collagenous gastroenteritis. ( 28862318 )
2017
28
Bullous hemorrhagic dermatosis due to enoxaparin use in a bullous pemphigoid patient. ( 28487841 )
2017
29
A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid. ( 27876358 )
2017
30
Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab. ( 28944534 )
2017
31
Mortality in bullous pemphigoid and prognostic factors in 1st and 3rd year of follow-up in specialized centre in Poland. ( 28852833 )
2017
32
Eosinophils as putative therapeutic targets in bullous pemphigoid. ( 28833620 )
2017
33
Localized bullous pemphigoid in a melanoma patient with dual exposure to PD-1 checkpoint inhibition and radiation therapy. ( 28884139 )
2017
34
Bullous Pemphigoid Associated with the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin in a Patient with Liver Cirrhosis Complicated with Rapidly Progressive Hepatocellular Carcinoma. ( 28824076 )
2017
35
The Role of Intereukin-31 in Pathogenesis of Itch and Its Intensity in a Course of Bullous Pemphigoid and Dermatitis Herpetiformis. ( 28808661 )
2017
36
Extensive milia formation in a young woman with bullous pemphigoid. ( 28440230 )
2017
37
Bullous pemphigoid associated with silicosis. ( 28622458 )
2017
38
Analysis of serum markers of cellular immune activation in patients with bullous pemphigoid. ( 28500685 )
2017
39
Scabies masquerading as bullous pemphigoid: scabies surrepticius. ( 28883737 )
2017
40
Failure of initial disease control in bullous pemphigoid: a retrospective study of hospitalized patients in a single tertiary center. ( 28856675 )
2017
41
Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments. ( 28413387 )
2017
42
Bullous pemphigoid and systemic sclerosis: an incidental association? ( 28468735 )
2017
43
Variation of the epidermal expression of glucocorticoid receptor-beta as potential predictive marker of bullous pemphigoid outcome. ( 28887823 )
2017
44
The anti-C1s antibody TNT003 prevents complement activation in the skin induced by bullous pemphigoid autoantibodies. ( 28899686 )
2017
45
Complement-independent blistering mechanisms in bullous pemphigoid. ( 28418613 )
2017
46
Linagliptin-induced bullous pemphigoid. ( 28762465 )
2017
47
Increased Risk of Bullous Pemphigoid after First-Ever Stroke: A Population-Based Study. ( 28467996 )
2017
48
Glucocorticoids: the mode of action in bullous pemphigoid. ( 28771827 )
2017
49
Bullous pemphigoid induced by photodynamic therapy: when light is guilty. ( 28369769 )
2017
50
Increased expression of NLRP3 inflammasome components and interleukin-18 in patients with bullous pemphigoid. ( 27174093 )
2016

Variations for Bullous Pemphigoid

Expression for Bullous Pemphigoid

Search GEO for disease gene expression data for Bullous Pemphigoid.

Pathways for Bullous Pemphigoid

Pathways related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

(show all 26)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.78 CCL11 CCL17 COL17A1 DSP IL5 ITGA6
2
Show member pathways
13.31 CCL11 CCL17 COL17A1 ITGA6 ITGB4 LAMA3
3
Show member pathways
12.94 CD79A COL17A1 ITGA6 ITGB4 LAMA3 LAMB3
4
Show member pathways
12.79 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
5
Show member pathways
12.76 CCL11 HLA-DQB1 HLA-DRB1 IL5 RNASE3
6
Show member pathways
12.7 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
7
Show member pathways
12.58 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3
8
Show member pathways
12.4 DSG1 DSG3 DSP EVPL PPL
9
Show member pathways
12.21 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3
10
Show member pathways
12.18 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
11
Show member pathways
12.07 HLA-DQB1 HLA-DRB1 ITGA6 LAMA3 LAMB3 LAMC2
12
Show member pathways
11.98 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
13
Show member pathways
11.9 DSG1 DSG3 DSP PLEC
14
Show member pathways
11.85 COL17A1 DST ITGA6 ITGB4 LAMA3 LAMB3
15 11.84 DSP ITGA6 ITGB4 PLEC
16
Show member pathways
11.8 DSP DST EVPL PLEC PPL
17 11.78 LAMA3 LAMB3 LAMC2
18 11.76 HLA-DQB1 HLA-DRB1 IL5 ITGA6
19 11.68 ITGA6 LAMA3 LAMB3 LAMC2
20 11.57 CCL11 CCL17 IL5
21 11.57 CCL11 DSP IL5
22 11.55 LAMA3 LAMB3 LAMC2
23 11.5 DSG1 HLA-DQB1 HLA-DRB1
24 11.41 CCL11 CCL17 IL5
25
Show member pathways
11.38 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
26 11.19 COL17A1 ITGA6 ITGB4

GO Terms for Bullous Pemphigoid

Cellular components related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell junction GO:0030054 9.97 COL17A1 DSG1 DSG3 DSP DST EVPL
2 cornified envelope GO:0001533 9.65 DSG1 DSG3 DSP EVPL PPL
3 basement membrane GO:0005604 9.63 COL17A1 DST ITGA6 LAMA3 LAMB3 LAMC2
4 laminin-5 complex GO:0005610 9.37 LAMA3 LAMB3
5 desmosome GO:0030057 9.35 DSG1 DSG3 DSP EVPL PPL
6 hemidesmosome GO:0030056 9.02 COL17A1 DST ITGA6 ITGB4 PLEC
7 extracellular exosome GO:0070062 10.14 DSG1 DSG3 DSP DST EVPL HLA-DRB1

Biological processes related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.92 CCL11 CCL17 HLA-DQB1 HLA-DRB1 IL5
2 cell adhesion GO:0007155 9.81 CCL11 DSG1 DSG3 DST ITGA6 ITGB4
3 extracellular matrix organization GO:0030198 9.77 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2
4 single organismal cell-cell adhesion GO:0016337 9.74 DSG1 DSP ITGA6
5 cell-matrix adhesion GO:0007160 9.73 COL17A1 ITGA6 ITGB4
6 integrin-mediated signaling pathway GO:0007229 9.72 DST ITGA6 ITGB4
7 keratinization GO:0031424 9.72 DSG1 DSG3 DSP EVPL PPL
8 extracellular matrix disassembly GO:0022617 9.69 LAMA3 LAMB3 LAMC2
9 cornification GO:0070268 9.65 DSG1 DSG3 DSP EVPL PPL
10 skin development GO:0043588 9.61 DSP ITGA6 ITGB4
11 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.54 HLA-DQB1 HLA-DRB1
12 amelogenesis GO:0097186 9.49 ITGA6 ITGB4
13 nail development GO:0035878 9.48 ITGA6 ITGB4
14 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.46 HLA-DQB1 HLA-DRB1
15 epidermis development GO:0008544 9.43 COL17A1 DSP EVPL LAMA3 LAMB3 LAMC2
16 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.4 HLA-DQB1 HLA-DRB1
17 hemidesmosome assembly GO:0031581 9.17 COL17A1 ITGA6 ITGB4 LAMA3 LAMB3 LAMC2

Molecular functions related to Bullous Pemphigoid according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cadherin binding GO:0045296 9.62 EVPL ITGA6 PLEC PPL
2 insulin-like growth factor I binding GO:0031994 9.26 ITGA6 ITGB4
3 structural molecule activity GO:0005198 9.26 DSP EVPL LAMA3 LAMB3
4 MHC class II receptor activity GO:0032395 9.16 HLA-DQB1 HLA-DRB1
5 neuregulin binding GO:0038132 8.62 ITGA6 ITGB4

Sources for Bullous Pemphigoid

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....